News
Company News: ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel Therapeutic Antibody to Treat Inflammatory Rheumatic Diseases
– Company forms international consortium with ProteoGenix SAS and Amsterdam UMC
ImmunOs Therapeutics AG, a Swiss bio-technology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that it has received public funding from the European Union’s Eurostars-2 Programme and the Swiss Innovation Agency Innosuisse. The funds have been granted for the development of a pioneering HLA-open conformer-specific antibody to treat chronic inflammatory rheumatic diseases. Research will be conducted by a consortium with ProteoGenix SAS (Strasbourg, France) and Amsterdam University Medical Centres (Amsterdam, The Netherlands).
Company News: T-knife Therapeutics Announces the Appointment of Donald Wuchterl as Senior Vice President and Chief Manufacturing Officer
T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing innovative therapeutics for the benefit of solid tumor patients and their families, today announced the appointment of Donald Wuchterl as Senior Vice President and Chief Manufacturing Officer. In this newly appointed role, Mr. Wuchterl will oversee process and analytical development, quality assurance and quality control, and viral vector and cell therapy manufacturing activities.
Company News: Pan Cancer T B.V. Appoints Seasoned Entrepreneurs and Executives to its Supervisory Board and Elects its Chairman
– John Tchelingerian, PhD (Chair), Dharminder Singh Chahal and Prof. Dr. Chris Bangma to form Supervisory Board
Pan Cancer T B.V., a biotech company discovering and developing first-in-class T-cell receptor (TCR) T-cell therapy for hard-to-treat solid tumors, today announced the appointment of John Tchelingerian, PhD, as Chairman and of Dharminder Singh Chahal and Prof. Dr. Chris Bangma as members of the Supervisory Board. This marks an important step in the development of the Company and is aligned with its ambitious goals regarding financing, deal-making, and cancer immunotherapy.
Company News: Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior’s First-in-Class Heart Failure Program
— Publication of international research group in Frontiers in Cardiovascular Medicine confirms key role of miR-132 in cardiovascular diseases
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that a recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure.